Last reviewed · How we verify
Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
This is an exploratory study that will evaluate the safety and pharmacodynamics of up to 3 doses of AGN-207281 based on an ongoing review of data during the study period compared with timolol ophthalmic solution or placebo in patients with ocular hypertension or primary open-angle glaucoma.
Details
| Lead sponsor | Allergan |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 50 |
| Start date | 2010-10 |
| Completion | 2010-12 |
Conditions
- Glaucoma, Open-Angle
- Ocular Hypertension
Interventions
- AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)
- timolol ophthalmic solution 0.5%
- AGN-207281 vehicle ophthalmic solution (Placebo)
Primary outcomes
- Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Day 14 — Baseline, Day 14
Change from baseline in worse eye IOP at day 14. Worse eye IOP refers to the eye with the worse (highest) baseline IOP (a measurement of the fluid pressure inside the eye). A negative number change from baseline indicates a reduction in IOP (improvement).
Countries
United States